# Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov

Source: https://onco.cc/trials/nct05456685/  
OnCo record `nct05456685` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mirvetuximab soravtansine, Carboplatin in ovarian cancer, run by AbbVie, active and no longer recruiting.

## Summary

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer is a phase 2 interventional study registered as NCT05456685 by AbbVie, with 125 participants enrolled, started 2022-09-28 and due to reach its primary completion in 2026-11. Interventions recorded: Mirvetuximab soravtansine, Carboplatin. Conditions listed: High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05456685
- Phase: 2
- Setting: Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy
- Sponsor: AbbVie
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT05456685: https://clinicaltrials.gov/study/NCT05456685

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct05456685.json